Skip to main content

David Charles Montefiori, PhD

Professor in Surgery
Office: Surgical Oncology Res Fac, Durham, NC 27710
Campus Mail: DUMC Box 2926 Med Ctr, Durham, NC 27710

Dr. Montefiori is Professor and Director of the Laboratory for AIDS Vaccine Research and Development in the Department of Surgery, Division of Surgical Sciences, Duke University Medical Center. His major research interests are viral immunology and AIDS vaccine development, with a special emphasis on neutralizing antibodies. One of his highest priorities is to identify immunogens that generate broadly cross-reactive neutralizing antibodies for inclusion in HIV vaccines.  Many aspects of the neutralizing antibody response are studied in his laboratory, including mechanisms of neutralization and escape, epitope diversity among genetic subtypes and geographic origins, ontogeny of broadly neutralizing antibody responses and computationally-assisted vaccine design. Over the years he has explored multiple types of assays for neutralizing antibodies and other potential antiviral antibodies, focusing on assay optimization, standardization, validation and high throughput. The scope of research covers HIV-infected individuals and nonhuman primate models of simian immunodeficiency virus (SIV) and simian-human immunodeficiency virus (SHIV) infection.  Dr. Montefiori also directs a large AIDS vaccine immune monitoring program, which operates in compliance with Good Clinical Laboratory Practice and has served as a national and international resource for standardized assessments of neutralizing antibody responses in preclinical and clinical trials of candidate AIDS vaccines since 1988. In 2002 he chaired the Antibody Laboratory Standardization Working Group that assisted in the design of the Global HIV Vaccine Enterprise Strategic Plan for HIV vaccines. He currently directs the Core Neutralizing Antibody Laboratories for the HIV Vaccine Clinical Trials Network (HVTN), the NIH Preclinical HIV-1 Vaccine Program and the Center for HIV/AIDS Vaccine Immunology- Immunogen Design (CHAVI-ID). He also directs a large Comprehensive Antibody Vaccine Immune Monitoring Consortium (CAVIMC) as part of the Bill and Melinda Gates Foundation's Collaboration for AIDS Vaccine Discovery (CAVD). He has published over 500 original research papers that have helped shape the scientific rationale for antibody-based HIV-1 vaccines.

Education and Training

  • Ph.D., Clemson University, 1982

Selected Grants

Publications

Huang, Yunda, Lily Zhang, Amanda Eaton, Nonhlanhla N. Mkhize, Lindsay N. Carpp, Erika Rudnicki, Allan DeCamp, et al. “Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants.” Hum Vaccin Immunother 18, no. 1 (December 31, 2022): 1908030. https://doi.org/10.1080/21645515.2021.1908030.

Full Text

Atmar, Robert L., Kirsten E. Lyke, Meagan E. Deming, Lisa A. Jackson, Angela R. Branche, Hana M. El Sahly, Christina A. Rostad, et al. “Homologous and Heterologous Covid-19 Booster Vaccinations.” N Engl J Med 386, no. 11 (March 17, 2022): 1046–57. https://doi.org/10.1056/NEJMoa2116414.

Full Text

Pajon, Rolando, Nicole A. Doria-Rose, Xiaoying Shen, Stephen D. Schmidt, Sijy O’Dell, Charlene McDanal, Wenhong Feng, et al. “SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination.” N Engl J Med 386, no. 11 (March 17, 2022): 1088–91. https://doi.org/10.1056/NEJMc2119912.

Full Text

Mu, Zekun, Kevin Wiehe, Kevin O. Saunders, Rory Henderson, Derek W. Cain, Robert Parks, Diana Martik, et al. “mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice.” Cell Rep 38, no. 11 (March 15, 2022): 110514. https://doi.org/10.1016/j.celrep.2022.110514.

Full Text

Chu, Laurence, Keith Vrbicky, David Montefiori, Wenmei Huang, Biliana Nestorova, Ying Chang, Andrea Carfi, et al. “Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial.” Nat Med, March 3, 2022. https://doi.org/10.1038/s41591-022-01739-w.

Full Text

Gay, Cynthia L., Katherine S. James, Marina Tuyishime, Shane D. Falcinelli, Sarah B. Joseph, Matthew J. Moeser, Brigitte Allard, et al. “Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat.” J Infect Dis 225, no. 5 (March 2, 2022): 856–61. https://doi.org/10.1093/infdis/jiab487.

Full Text

Sahoo, Anusmita, Edgar A. Hodge, Celia C. LaBranche, Tiffany M. Styles, Xiaoying Shen, Narayanaiah Cheedarla, Ayalnesh Shiferaw, et al. “Structure-guided changes at the V2 apex of HIV-1 clade C trimer enhance elicitation of autologous neutralizing and broad V1V2-scaffold antibodies.” Cell Rep 38, no. 9 (March 1, 2022): 110436. https://doi.org/10.1016/j.celrep.2022.110436.

Full Text

Del Moral-Sánchez, Iván, Rebecca A. Russell, Edith E. Schermer, Christopher A. Cottrell, Joel D. Allen, Alba Torrents de la Peña, Celia C. LaBranche, et al. “High thermostability improves neutralizing antibody responses induced by native-like HIV-1 envelope trimers.” Npj Vaccines 7, no. 1 (February 28, 2022): 27. https://doi.org/10.1038/s41541-022-00446-4.

Full Text

Sangare, K., S. H. Hait, M. Moore, C. Hogge, T. Hoang, M. A. Rahman, D. J. Venzon, et al. “E4orf1 Suppresses E1B-Deleted Adenovirus Vaccine-Induced Immune Responses.” Vaccines 10, no. 2 (February 1, 2022). https://doi.org/10.3390/vaccines10020295.

Full Text

Pages